Search results
Showing 961 to 975 of 1002 results for public health medicine & health
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Discontinued Reference number: GID-TA10961
In development Reference number: GID-TA11008 Expected publication date: TBC
This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]
Discontinued Reference number: GID-TA11264
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Discontinued Reference number: GID-TA11086
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
Discontinued Reference number: GID-TA11569
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]
Discontinued Reference number: GID-TAG420
Discontinued Reference number: GID-TAG387
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (HTG553)
Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke.
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
Routine NHS access to spinal muscular atrophy treatments offers new hope for patients and families
People living with spinal muscular atrophy (SMA) in England are set to gain routine access to two potentially life-changing treatments, following our publication of final draft guidance today.
NICE appoints Dr Adrian Hayter as its new chief medical officer
Dr Adrian Hayter joins NICE from the Royal College of General Practitioners bringing more than three decades of frontline clinical and national leadership experience to the role.
Have your say on NICE's adoption of the new EQ-5D-5L value set
We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of life.